Zepbound Outperforms Wegovy in Weight Loss Clinical Trial

Eli Lilly's Zepbound demonstrated significantly greater weight loss compared to Novo Nordisk's Wegovy in a 72-week head-to-head study.

Participants using Zepbound lost an average of 20.2% of their body weight, compared to 13.7% for those on Wegovy.
The trial showed 31% of Zepbound users lost at least 25% of their body weight, versus 16% for Wegovy users.
The study involved 751 adults in the U.S. and Puerto Rico who were overweight or had obesity with at least one comorbidity, excluding diabetes.
Zepbound, a dual GIP and GLP-1 receptor agonist, is designed to enhance satiety and slow digestion, leading to greater weight loss efficacy.
Experts emphasize that weight loss drugs require long-term commitment and should be paired with healthy lifestyle changes for sustained results.